BioMedNewsBreaks

TuesdayJun 16, 2026 1:57 pm

BioMedNewsBreaks — Humacyte Inc. (NASDAQ: HUMA) Prices $50 Million Public Offering 

Humacyte (NASDAQ: HUMA) announced the pricing of an underwritten public offering of 47.6 million shares of common stock at $1.05 per share, with expected gross proceeds of approximately $50 million before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 7.1 million shares at the public offering price. The offering is expected to close on or about June 12, 2026, subject to customary closing conditions. Humacyte said it intends to use the net proceeds to support commercialization of Symvess(R), advance a planned Biologics License Application supplement filing for a hemodialysis indication, fund development of pipeline candidates and provide working capital…

Continue Reading

TuesdayJun 16, 2026 1:27 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Positioned at Intersection of Telemedicine, Pharmacy, Healthcare Services

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its significant transformation over the past several years, positioning as a diversified holding company focused on pharmaceutical compounding, telemedicine, healthcare services, and strict capital allocation. “The company recently completed a vertically integrated telehealth and pharmacy ecosystem through the launch of MyOnlineConsultation.com, with telemedicine capabilities supporting patient acquisition, while pharmacy operations drive high-margin recurring prescription-based revenue streams,” reads a recent article. “Above all, Earth Science Tech emphasizes balance-sheet strength and capital discipline through ongoing share repurchase initiatives designed to reduce dilution and support shareholder value.” To view the full…

Continue Reading

TuesdayJun 16, 2026 1:01 pm

BioMedNewsBreaks — Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA Biotech (NASDAQ: VRXA) is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. “The company is focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave of smart cancer therapies with curative potential and improved safety profiles,” reads a recent article. “The company is building a pipeline that includes dual-targeting antibody-drug conjugates (‘ADCs’) and T-cell engagers (‘TCEs’) predominantly based on its patented BiTAC concept. This concept is designed to improve the…

Continue Reading

FridayJun 12, 2026 2:38 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Harnesses AI, Genetics and Epigenetics to Advance Cardiovascular Risk Detection

Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discusses the urgent need for more effective tools to identify risk earlier and guide personalized intervention strategies for cardiovascular disease. The piece reads, “Cardio Diagnostics is rising to the challenge by developing a suite of clinical, population health and biopharma solutions designed to leverage artificial intelligence (‘AI’), epigenetics and genetics to improve cardiovascular disease prevention, detection and management… The company’s platform is built around the integration of genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing. Cardio Diagnostics currently offers two clinical solutions, Epi+Gen…

Continue Reading

ThursdayJun 11, 2026 3:58 pm

BioMedNewsBreaks — OptimizeRx Corp. (NASDAQ: OPRX) Secures $35 Million Senior Credit Facility 

OptimizeRx (NASDAQ: OPRX), a provider of healthcare technology solutions for life sciences companies, announced that it has entered into a $35 million senior secured credit facility with Fifth Third Bank. The facility consists of a $25 million term loan and a $10 million revolving credit facility that was undrawn at closing. Roth Capital Partners served as financial advisor on the transaction. To view the full announcement, visit https://ibn.fm/G0Fj3 About OptimizeRx OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant,…

Continue Reading

ThursdayJun 11, 2026 2:32 pm

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Accelerates Development Strategy for Lead Candidate

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, was featured in a recent article that discussed the company’s efforts beginning a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. The publication reads, “The company is initiating a Good Laboratory Practice (‘GLP’) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (‘FDA’) requirements, intended to support an Investigational New Drug (‘IND’) application and represents a necessary step before first-in-human clinical trials.…

Continue Reading

ThursdayJun 11, 2026 10:40 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Completes Business Combination and Begins Trading on Nasdaq

VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue. VERAXA said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to…

Continue Reading

WednesdayJun 10, 2026 9:30 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Highlights Fiscal 2026 Growth and Cash Flow Progress in Shareholder Letter

Earth Science Tech (OTC: ETST) provided a business update in a letter to shareholders, highlighting what management described as a transformational fiscal year ended March 31, 2026. The company cited progress across multiple holdings, including the expansion of Mister Meds, turnarounds at DOConsultation and Villas Health, the relaunch of MyOnlineConsultation as a cash flow-positive prescriber network and revenue growth at Peaks that surpassed $2 million during the first week of the fourth quarter. Earth Science Tech said it completed these initiatives without adding debt to its balance sheet, while also repurchasing and retiring more than 3.7 million shares during the…

Continue Reading

WednesdayJun 10, 2026 9:10 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Advances ONC010 Manufacturing Process Development

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. The work represents a key milestone in the company's chemistry, manufacturing and controls strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation. Onco said the program will focus on optimizing synthetic processes, improving yield and reproducibility and scaling production of key intermediates required for downstream manufacturing and formulation. The…

Continue Reading

TuesdayJun 09, 2026 9:40 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio’s Edge AI Kiosks Use Voice and AI to detect intoxication and fatigue. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced the completion and delivery of its first prototype Edge AI Intoxication Detection Kiosks, a hardware and software platform designed to detect intoxication and fatigue through AI-powered voice analysis. The kiosks are intended for workplace environments and are being developed to help improve safety across industries where drug, alcohol and fatigue monitoring are critical. The company said the prototypes will now undergo testing,…

Continue Reading